News Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Real-time Estimate Cboe BZX Other stock markets 09:57:48 29/04/2024 pm IST			5-day change	1st Jan Change
2.995 ^USD	+2.39%		-5.57%	+53.59%

22/04	Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	MT
05/04	Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	22/04	MT
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing	05/04	AQ
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	05/04	AQ
Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	05/04	CI
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	05/04	AQ
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	05/04	CI
Protara Therapeutics, Inc. Announces Resignation of Jathin Bandari as Chief Medical Officer, Effective April 11, 2024	19/03	CI
Protara Therapeutics: Q4 Earnings Snapshot	13/03	AQ
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03	CI
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	13/03	AQ
Proteon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
North American Morning Briefing : Stock Futures -2-	13/03	DJ
Top Premarket Gainers	12/03	MT
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	28/02	AQ
Top Premarket Decliners	12/02	MT
Protara Therapeutics to Participate in Upcoming Investor Conferences	31/01	AQ
Top Premarket Decliners	17/01	MT
Protara Therapeutics Says 5 of 6 Patients in Dose Escalation Portion of Bladder Cancer Trial Showed Recurrence-Free Survival	30/11	MT
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology	30/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Summary

Filters